Inicio › Enfermedad pulmonar intersticial › Arizona
Ensayos clínicos de Enfermedad pulmonar intersticial en Arizona
13 estudios sobre Enfermedad pulmonar intersticial buscan participantes en Arizona.
Ciudades en Arizona
Texto oficial del estudio (inglés)
Efficacy and Safety Study of Treprostinil Palmitil Inhalation Powder (TPIP) in Participants With Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)
- USA027, Phoenix
ReclutandoFase 3
Edades de 18 en adelante · Todos los sexos · Actualizado el 29 sept 2026 · NCT07179380LAM-001 for the Treatment of Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)
- Arizona Heart Rhythm Center, Phoenix
- University of Arizona, Tucson
ReclutandoFase 2
Edades de 18 a 80 · Todos los sexos · Actualizado el 29 sept 2026 · NCT05798923Study of TX000045 in Participants With Pulmonary Hypertension Due to Interstitial Lung Disease
- Phoenix, Phoenix
ReclutandoFase 2
Edades de 18 a 80 · Todos los sexos · Actualizado el 8 sept 2026 · NCT07473700A Study of the Efficacy and Safety of Belimumab in Adults With Systemic Sclerosis Associated Interstitial Lung Disease
- GSK Investigational Site, Scottsdale
- GSK Investigational Site, Scottsdale
- GSK Investigational Site, Tucson
ReclutandoFase 2/3
Edades de 18 en adelante · Todos los sexos · Actualizado el 8 sept 2026 · NCT05878717Multi-site Study of the Clinical Impact of an AI-assisted Approach to Referring Patients With Interstitial Lung Disease for Diagnostic Evaluation of Pulmonary Hypertension
- Banner University Medical Center, Phoenix
- Dignity Health - St. Joseph's Hospital and Medical Center-Norton Thoracic Institute, Phoenix
Reclutando
Edades de 18 en adelante · Todos los sexos · Actualizado el 2 sept 2026 · NCT06911632A Phase 3 Study to Evaluate the Safety and Efficacy L606 in Participants With PH-ILD
- Dignity Health - St. Joseph's Hospital and Medical Center, Phoenix
- Arizona Pulmonary Specialists, Ltd., Scottsdale
ReclutandoFase 3
Edades de 18 a 80 · Todos los sexos · Actualizado el 2 sept 2026 · NCT07285655DeciPHer-ILD: A Real-world Patient Registry in Group 3 Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)
- Banner Health - University Medical Center Phoenix, Phoenix
ReclutandoEstudio observacional
Edades de 18 en adelante · Todos los sexos · Actualizado el 26 ago 2026 · NCT06388421Idiopathic Pulmonary Fibrosis and Interstitial Lung Disease Prospective Outcomes Registry
- University of Arizona, Tucson
ReclutandoEstudio observacional
Edades de 21 en adelante · Todos los sexos · Actualizado el 12 ago 2026 · NCT01915511A Study of ROC-101 in Patients With Pulmonary Arterial Hypertension (PAH) and Pulmonary Hypertension Associated With Interstitial Lung Disease (ILD-PH) (ROCSTAR STUDY)
- Arizona Pulmonary Specialists, Phoenix
ReclutandoFase 2
Edades de 18 a 80 · Todos los sexos · Actualizado el 10 ago 2026 · NCT07175038Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Progressive Pulmonary Fibrosis (TETON-PPF)
- Banner University Medical Center Phoenix Lung Institute, Phoenix
- Norton Thoracic Institute, Phoenix
ReclutandoFase 3
Edades de 18 en adelante · Todos los sexos · Actualizado el 13 jul 2026 · NCT05943535An Open-Label ProSpective MultiCENTer Study to Evaluate Safety and Tolerability of Dry Powder Inhaled Treprostinil in PH
- Arizona Pulmonary Specialists, Phoenix
ReclutandoEstudio observacional
Edades de 18 a 80 · Todos los sexos · Actualizado el 26 jun 2026 · NCT06129240Home-based Pulmonary Rehabilitation and Health Coaching in Patients With Fibrotic Interstitial Lung Disease
- Mayo Clinic in Arizona, Scottsdale
Reclutando
Edades de 18 en adelante · Todos los sexos · Actualizado el 20 mar 2026 · NCT06751069Study Evaluating INS018_055 Administered Orally to Subjects With Idiopathic Pulmonary Fibrosis
- HonorHealth Research Institute, Scottsdale
ReclutandoFase 2
Edades de 40 en adelante · Todos los sexos · Actualizado el 12 nov 2025 · NCT05975983De ClinicalTrials.gov, datos obtenidos el 5 oct 2026. Cada estudio establece sus propios criterios de elegibilidad; el equipo del estudio decide quién puede participar.